WO2024261641 - TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES WITH 1H-INDOLE-3-CARBOXALDEHYDE OR 1-METHYLINDOLE-3-CARBOXYLIC ACID
National phase entry is expected:
Publication Number
WO/2024/261641
Publication Date
26.12.2024
International Application No.
PCT/IB2024/055943
International Filing Date
18.06.2024
Title **
[English]
TREATMENT OF PRIMARY CTLA-4 CHECKPOINT RELATED IMMUNODEFICIENCIES WITH 1H-INDOLE-3-CARBOXALDEHYDE OR 1-METHYLINDOLE-3-CARBOXYLIC ACID
[French]
TRAITEMENT D'IMMUNODÉFICIENCES ASSOCIÉES AU POINT DE CONTRÔLE CTLA-4 PRIMAIRE AVEC DE L'ACIDE 1H-INDOLE-3-CARBOXALDÉHYDE OU DE L'ACIDE 1-MÉTHYLINDOLE-3-CARBOXYLIQUE
Applicants **
ADIENNE PHARMA & BIOTECH SA
Via Zurigo N. 46
6900 Lugano, CH
Inventors
DI NARO, Antonio Francesco
Via San Bartolomee 7
6922 Morcote, CH
GIOVAGNOLI, Stefano
1 Via del Liceo
06123 Perugia, IT
PUCCETTI, Matteo
1 Via del Liceo
06123 Perugia, IT
PARIANO, Marilena
1 P.le Lucio Severi
06123 Perugia, IT
Priority Data
63/509,223
20.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1934 | |
| EPO | Filing, Examination | 10325 | |
| Japan | Filing | 532 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4685 |
Total: 18051 USD
Abstract[English]
The present disclosure is directed to a method of treating a CTLA-4 checkpoint related immunodeficiency by administering a therapeutically effective amount of a pharmaceutical composition comprising 1H-indole-3-carboxaldehyde (3-IAld) or 1-methylindole-3-carboxylic acid.[French]
La présente invention concerne une méthode de traitement d'une immunodéficience associée au point de contrôle CTLA-4 par administration d'une quantité thérapeutiquement efficace d'une composition pharmaceutique comprenant de l'acide 1H-indole-3-carboxaldéhyde (3-IAld) ou de l'acide 1-méthylindole-3-carboxylique.